This study aimed to evaluate the impact of ICT, EPO, ATG, and LENA on OS and the risk of progression to AML in patients with MDS who are ineligible for allogeneic SCT or had an MDS profile where SCT was not initially indicated. This evidence concerns the gene EPO and myelodysplastic syndrome.